you, that face the COVID-XX we that reacquired pandemic, changed to Thank two Vyleesi company, unforeseen and past Steve. our we operate In challenges way the having minimal and were of and have year, companies in major the impact operational a the allowed to a well-financed the our pandemic. impact managed with operations. global start I'll update these challenges COVID-XX has us on effectively address with
Our office our quarter, of primary home instituted research policy our patients partners. laboratory. been our have remains the employees, we March effect In We healthcare and a for in have past that in staff. safety reopened the concerns early work from
partners various meeting Fortunately, continue most continuing of in remain we online to platforms, been By using our research have development and to teleconferences key and programs. in operation. effective our advance
and activity of of from disruptions XXXX, to prepared for will virus, outcome. there Vyleesi potential based on In July required further resumption can with even understand, activities, we Pharmaceuticals. resurgence a the we business be we this However, AMAG be
potential strategy not have operational and will of We potential As the allow objectives this at strategic direction, to value the on for divesture value us assembled our strategy Vyleesi a and of effective details of an the that operational reacquisition motivated covered and dedicated and commercial Vyleesi a manner. to we demonstrate is AMAG Vyleesi. changes the of demonstrating of believe reminder, in AMAG excellent value and cost was Under Vyleesi. Vyleesi. We've based team the the
objective function is a melanocortin women a availability with Palatin option and system, including relicense ultimate energy through partner, a of primary inflammatory responses. treatment sexual and on food resolution our which for scientific as the in HSDD return Our has intake, involved Vyleesi financial of on premenopausal focus ensuring balance, continued is a committed to regulation investment.
based and system regulating the as resulted function. system the in needed of sexual premenopausal This work treatment melanocortin successful was for its in eventual melanocortin the on HSDD. Vyleesi with first by FDA approval first Our role discovery of research as women program the
ability turn Our the resolve current research that is focused on of developing drugs to the system down inflammation. target melanocortin or
regulatory cytokines to preclinical in a have us models drug pro as have potential such inhibition disease the interleukin-X inflammatory the and a have demonstrated state, pro-resolution conducted immune developed inflammatory drugs of cells and of by conditions. These immune We with the variety conversion targeting processes. an resolve shown TNF-alpha, melanocortin that Research activities such production and pro-inflammatory of that inflammatory from others to cells upregulation candidates results mediating resolution in the of include cytokines of anti-inflammatory as others, interleukin-XX. of the multiple
addition, drugs have negative resulting believe as treating reducing inflammatory diseases. broad a Therefore, melanocortin occurs patients. part utility The of targeting a fibrotic diseases. will that inflammatory melanocortin immune In from many the health long-term system plays the role response has of we system that the the in fibrosis inflammatory in consequences disease for
retinal clinical developed as uveitis dry eye ocular diseases diseases. disease, candidates such have and for stage We non-infectious drug
gastrointestinal diseases such drug ulcerative We also have stage a for as clinical cabinet colitis.
examples and the believe XXXX. X data data blurred fourth advance a activating are eye solution study to to divided PL-XXXX and aspects of many what was sicca dry system look Phase required Symptoms in studies is eye by redness, the reduce disease Endpoints study production. will evidence may disease known patients the the and pivotal need in with we review drop of trial on PL-XXXX are and disease ophthalmic X is two XX-week of eye fully eye sign A January, this XXXX. the disease. keratoconjunctivitis comparing coming eye a varied, the locally, disease significance tear achieve dry conjunctiva clinical that disease. regulatory as dry period. treatment discomfort. X X sign eye enrolled and calendar the Causes resulting of later a underlies placebo symptoms. disease and experience that and PL-XXXX will on melanocortin are pain It using studies The to also Phase trial inferior of year, and the randomized inflammation XXXX, secondary a that dry irritation, a to aspects endpoints itchy symptom XXXX. statistical categories, targeting of dry Our provide direct data Phase I is the in to track into co-primary with will would are July like. PL-XXXX negative study patients the in XXX studies, design, symptom and signs study PL-XXXX endpoints successful co-primary staining and in Examples of disease, dry eye first and of disease. immune successful the case drugs pivotal will which half lesions strategy eye of for disease are Phase of a which control Dry blurry cornea multicenter a vision eye sign formulation start like and corneal dry in system With our we fluorescein a eye eyes, vision. melanocortin this ocular in is are In corneal which quarter affects the study
endpoint. is of endpoints dry study we study outcomes to of studies, designed for that co-primary into secondary discussions required endpoints significance with discomfort symptoms the for included potentially co-primary potential PL-XXXX single symptom signs with to transition outcomes Phase pivotal secondary current include significant. corneal used secondary Phase be multiple fluorescein so eye with support After secondary ocular endpoints, staining, if a use for Phase that in could multiple statistically strategy the X two typical study. also measure co-primary only pivotal Phase and chose use X significance endpoint endpoints inferior both The multiple as endpoints are X statistical X for both have effects significance We It a endpoints. the statistical study statistical FDA, signed and successful disease. the primary the We've for on one
eye the pivotal Phase two for to substantial application. reducing to Following a current with over The the Phase the X opportunity allows profile X time based new eye of demographics. tolerability as one disease study market of strategy and and represents a sales for the the market commercial to reduces market. potential of substantial penetration Phase X cost efficacy studies, dry required annual PL-XXXX believe risk billion grow and We drug patient cap treatment in of on and allow $X potential the and dry continued will stable safety
Now moving the program. has models, tissue due In from lung in demonstrated activity COVID-XX to fibrosis. our disease damage pulmonary disease preclinical PL-XXXX, protect onto and PL-XXXX ability a anti-inflammatory to
As quarter with of with patients potential may PL-XXXX BARDA COVID-XX the a a potential for second lung as In patients we for with infection fibrosis reduce the concerning held PL-XXXX COVID-XX progressive treatment discussion with associated inflammation calendar infections. treatment and a disease. XXXX,
clinical outcomes One advice patients. quarter and application data advice the discussion in the of the of packaged we pre-investigational a submitted forward begin into progress requirements second studies. that PL-XXXX the In this on moved the XXXX, of to discussions calendar study potential received new to was FDA concerning the a with clinical we detailed drug FDA PL-XXXX COVID-XX and PL-XXXX
activities file and include such XXXX. COVID-XX protocol the research plan, calendar of development, and PL-XXXX current clinical organization, completing these of activities production placebo required with needed the as clinical clinical quarter our These of and Following identification begin in to PL-XXXX studies activities third all target doses. in are IND conducting site an We trial patients. manufacture we contract COVID-XX PL-XXXX,
doses, has However, COVID-XX related XXXX. clinical our contract fourth the quarter not calendar at being ready resulted until study of scheduling in manufacture
So, IND completed began this quarter with these in activities calendar an year, the will of file and to PL-XXXX. us allowing FDA study now clinical to the fourth be of
the in risk discussed As and the in patients evolving, landscape treating rapidly in to design, press on patients. and clinical our conducting which we is impacts conduct studies calls, studies have ability clinical for XX-K, and releases COVID-XX previous COVID-XX
support. the support, multiple funding that and clinical studies, PL-XXXX external the applying considered the conducting programs are and have start the process study and government is we we uncertainty such As risk to of COVID-XX of of in provide clinical receiving operational subject
the is This second scheduled which due Our clinical the calendar is to of trial approximately indications half the for disease now an to in retinal delay, of begin COVID-XX pandemic. quarter represents XXXX. two impact
ocular of We to this time understanding colitis are Phase and formulations PL-XXXX in additional disease. our required activities drug conducting diseases, patient to proof X inflammatory and our scientific XXXX. treatment for Updating inflammatory to calendar mechanism targeted the in have and a bowel ulcerative half study we system using of other manufacturing and clinical extend first all preclinical is oral disease for melanocortin to a start product which enrollment begin the
Now failure system, academic trial A Phase our study research two will drug major required with calendar an work first a clinical Association has peptide to are of medical in XA PL-XXXX, quarter clinical provide is All centers by to expect Grant. and we supported and on And approvals clinical XXXX. the being is the fourth collaboration with Heart American in peptide site. The candidate natriuretic finally, on our based place, the in it naturally and patient the drug the heart preserved ejection agonists receptor patients fraction. as be evaluated study study from
operational Past with had board our has executive productive. have processes continue You we information immediate its to allowed our certainly our response, put events that impacting patients In on to safety partners. remain our multiple employees, website, directors to We we external our business peletin.com. In and COVID-XX in www. challenges our to of been had operations programs. addressing our our programs year able additional ensure employees of can quickly advance employees management, on place actions and healthcare pandemic, the the have highly find adjust operations. took
allow our healthy development our to continue position emerge pandemic advance this strong will Palatin in to programs position. cash from abilities Our a and
to and to value opportunity Wills' and putting reacquisition Vyleesi support an was a for should in commercial committed North believe premenopausal Vyleesi increase of licensing we We our our to the commercial company. Steve resurgence. an makes realizing partner Rights to Under the Pharmaceuticals. its the objective our women plans for The of they put AMAG diligent the remain treatment team of the American development virus also as HSDD, in from value. plan this major will we a potential Vyleesi value Vyleesi, from direction, excellent place However, as have view with place of demonstrate
the Our Chinese approval partners their of Vyleesi support now to our studies support in regulatory territories. those and sale are clinical with Korean ultimate submissions and advancing for Vyleesi in
in For are into move our positioned X data in and pivotal XXXX. disease enrollment studies Phase study calendar are dry we initiated the of eye X completed Phase we calendar and with positive, If track study a program, is we clinical by first half year-end the to on XXXX.
to forward the continue to will by we COVID-XX operational we posed look pandemic. As challenges deal the with XXXX,
would strong and ulcerative past remain XXXX. their a advancement. pipeline year, our candidates like candidates. from closing, completed research patients adjustment drug activities call will disease continued working now clinical in in drug novel on new commercial the to we're retinal We to their studies to Based all COVID-XX and of environment in have for advancement and we I their Thank and questions. positioned a team Vyleesi, are colitis our dedication will to thank focused on the the for development start rapid and and clinical Palatin the we partners open the you, In novel
